Drug therapy towards tumours often causes adverse effects because of their non-specific nature.Membrane-coated technology and membrane-coated nanoparticles provide an advanced and promising platform of targeted and sa...Drug therapy towards tumours often causes adverse effects because of their non-specific nature.Membrane-coated technology and membrane-coated nanoparticles provide an advanced and promising platform of targeted and safe delivery.By camouflaging the nanoparticles with natural derived or artificially modified cell membranes,the nano-payloads are bestowed with properties from cell membranes such as longer circulation,tumour or inflammation-targeting,immune stimulation,augmenting the performance of traditional therapeutics.In this review,we review the development of membrane coating technology,and summarise the technical details,physicochemical properties,and research status of membrane-coated nanoparticles from different sources in tumour treatment.Finally,we also look forward to the prospects and challenges of transforming membrane coating technology from experiment into clinical use.Taken together,membrane-coated nanoparticles are bound to become one of the most potential anti-tumour strategies in the future.展开更多
Parkinson’s disease(PD),a neurodegenerative disease that shows a high incidence in older individuals,is becoming increasingly prevalent.Unfortunately,there is no clinical cure for PD,and novel anti-PD drugs are there...Parkinson’s disease(PD),a neurodegenerative disease that shows a high incidence in older individuals,is becoming increasingly prevalent.Unfortunately,there is no clinical cure for PD,and novel anti-PD drugs are therefore urgently required.However,the selective permeability of the blood–brain barrier(BBB)poses a huge challenge in the development of such drugs.Fortunately,through strategies based on the physiological characteristics of the BBB and other modifications,including enhancement of BBB permeability,nanotechnology can offer a solution to this problem and facilitate drug delivery across the BBB.Although nanomaterials are often used as carriers for PD treatment,their biological activity is ignored.Several studies in recent years have shown that nanomaterials can improve PD symptoms via their own nano-bio effects.In this review,we first summarize the physiological features of the BBB and then discuss the design of appropriate brain-targeted delivery nanoplatforms for PD treatment.Subsequently,we highlight the emerging strategies for crossing the BBB and the development of novel nanomaterials with anti-PD nano-biological effects.Finally,we discuss the current challenges in nanomaterial-based PD treatment and the future trends in this field.Our review emphasizes the clinical value of nanotechnology in PD treatment based on recent patents and could guide researchers working in this area in the future.展开更多
The origins of controlled release drug delivery could be dated back to the 1950s.The Spansule technology was developed to deliver a drug for 12 h in 1952.Compared with taking a drug every 6 h or every8 h,twice-a-day f...The origins of controlled release drug delivery could be dated back to the 1950s.The Spansule technology was developed to deliver a drug for 12 h in 1952.Compared with taking a drug every 6 h or every8 h,twice-a-day formulation was revolutionary in improving the patients’compliance and convenience1.Since then,advances in drug delivery technologies have introduced numerous formulations展开更多
Dr.Jianxin Wang is a professor of pharmaceutics at Fudan University,School of Pharmacy.He received his Ph.D.in pharmaceutics from West China University of Medical Sciences in 1999.He worked for Shanghai Institute of C...Dr.Jianxin Wang is a professor of pharmaceutics at Fudan University,School of Pharmacy.He received his Ph.D.in pharmaceutics from West China University of Medical Sciences in 1999.He worked for Shanghai Institute of Chinese Materia Medica from July 1999 to April 2005.Dr.Wang became a faculty member of School of Pharmacy,Fudan University in 2005.He worked as a visiting scholar in the College of Pharmacy,展开更多
Hepatic carcinoma(HC)is the sixth most frequently occurring malignancies and the third leading cause of cancer death worldwide.Sepantronium bromide(YM155)is a small molecule inhibitor of survivin,which has broad-spect...Hepatic carcinoma(HC)is the sixth most frequently occurring malignancies and the third leading cause of cancer death worldwide.Sepantronium bromide(YM155)is a small molecule inhibitor of survivin,which has broad-spectrum anticancer therapeutic effects in various xenograft models.However,several-day continuous infusion is required to achieve greater antitumor efficacy because of rapid elimination from the blood circulation.Herein,a SMMC-7721 cancerous cyto-membrane-cloaked drug delivery system(DDS)(named as iM7721@GQD-YM),was developed for co-encapsulation of YM155 and graphene quantum dots(GQDs).Cytomembrane coating endowed iM7721@GQD-YM with effective targeting for homologous HC cells,excellent biocompatibility and favorable immunocompatibility for in vivo application.Surface decoration of iRGD peptide further enhanced its tumor targeting activity by iRGD-integrin recognition.In addition,under the irradiation of near-infrared ray(NIR),GQDs can directly kill tumors through photothermal effect and cause cell membrane rupture,accurately releasing YM155 at tumor sites.The physicochemical properties,in vivo and ex vivo anti-tumor efficacy,and mechanisms of iM7721@GQD-YM nanoparticles(NPs)were systematically investigated in this work.The experimental results clearly indicate that the versatile biomimetic DDS holds great potential for the treatment of HC,which merits further investigation in both pre-clinical and clinical studies.展开更多
RNAi technology has aroused wide public interest due to its high efficiency and specificity to treat multiple types of diseases. However, the effective delivery of siRNA remains a challenge due to its large molecular ...RNAi technology has aroused wide public interest due to its high efficiency and specificity to treat multiple types of diseases. However, the effective delivery of siRNA remains a challenge due to its large molecular weight and strong anionic charge. Considering their remarkable functions in vivo and features that are often desired in drug delivery carriers, biomimetic systems for siRNA delivery become an effective and promising strategy. Based on this, covalent attachment of synthetic cell penetrating peptides(CPP) to siRNA has become of great interest. We developed a monomeric covalent conjugate of low molecular weight protamine(LMWP, a well-established CPP) and siRNA via a cytosol-cleavable disulfide linkage using PEG as a crosslinker. Results showed that the conjugates didn't generate coagulation, and exhibited much better RNAi potency and intracellular delivery compared with the conventional charge-complexed CPP/siRNA aggregates. Three different synthetic and purification methods were compared in order to optimize synthesis efficiency and product yield. The methodology using hetero-bifunctional NHS–PEG–OPSS as a crosslinker to synthesize LMWP–siRNA simplified the synthesis and purification process and produced the highest yield. These results pave the way towards siRNA biomimetic delivery and future clinical translation.展开更多
文摘Drug therapy towards tumours often causes adverse effects because of their non-specific nature.Membrane-coated technology and membrane-coated nanoparticles provide an advanced and promising platform of targeted and safe delivery.By camouflaging the nanoparticles with natural derived or artificially modified cell membranes,the nano-payloads are bestowed with properties from cell membranes such as longer circulation,tumour or inflammation-targeting,immune stimulation,augmenting the performance of traditional therapeutics.In this review,we review the development of membrane coating technology,and summarise the technical details,physicochemical properties,and research status of membrane-coated nanoparticles from different sources in tumour treatment.Finally,we also look forward to the prospects and challenges of transforming membrane coating technology from experiment into clinical use.Taken together,membrane-coated nanoparticles are bound to become one of the most potential anti-tumour strategies in the future.
基金This work was financially supported through grants from the Guangdong Basic and Applied Basic Research Foundation(2019B1515120043)National Natural Science Foundation of China(File No.82104354)+2 种基金the Science and Technology Development Fund,Macao SAR(File No.0016/2021/A)and the Open Project of Key Laboratory of Modern Preparation of Traditional Chinese Medicine,Ministry of Education,Jiangxi University of Chinese Medicine(zdsys-202101)Open access funding provided by Shanghai Jiao Tong University
文摘Parkinson’s disease(PD),a neurodegenerative disease that shows a high incidence in older individuals,is becoming increasingly prevalent.Unfortunately,there is no clinical cure for PD,and novel anti-PD drugs are therefore urgently required.However,the selective permeability of the blood–brain barrier(BBB)poses a huge challenge in the development of such drugs.Fortunately,through strategies based on the physiological characteristics of the BBB and other modifications,including enhancement of BBB permeability,nanotechnology can offer a solution to this problem and facilitate drug delivery across the BBB.Although nanomaterials are often used as carriers for PD treatment,their biological activity is ignored.Several studies in recent years have shown that nanomaterials can improve PD symptoms via their own nano-bio effects.In this review,we first summarize the physiological features of the BBB and then discuss the design of appropriate brain-targeted delivery nanoplatforms for PD treatment.Subsequently,we highlight the emerging strategies for crossing the BBB and the development of novel nanomaterials with anti-PD nano-biological effects.Finally,we discuss the current challenges in nanomaterial-based PD treatment and the future trends in this field.Our review emphasizes the clinical value of nanotechnology in PD treatment based on recent patents and could guide researchers working in this area in the future.
文摘The origins of controlled release drug delivery could be dated back to the 1950s.The Spansule technology was developed to deliver a drug for 12 h in 1952.Compared with taking a drug every 6 h or every8 h,twice-a-day formulation was revolutionary in improving the patients’compliance and convenience1.Since then,advances in drug delivery technologies have introduced numerous formulations
文摘Dr.Jianxin Wang is a professor of pharmaceutics at Fudan University,School of Pharmacy.He received his Ph.D.in pharmaceutics from West China University of Medical Sciences in 1999.He worked for Shanghai Institute of Chinese Materia Medica from July 1999 to April 2005.Dr.Wang became a faculty member of School of Pharmacy,Fudan University in 2005.He worked as a visiting scholar in the College of Pharmacy,
基金“One Belt One Road”International Cooperation Project of Shanghai Municipal Committee of Science and Technology(No.19410740900)the National Natural Science Foundation of China(No.52002239)+1 种基金the International Science and Technology Cooperation Programme of Ministry of Science and Technology of China(No.2019YFE0116800)Natural Science Foundation of Shanghai(No.21ZR1422800).
文摘Hepatic carcinoma(HC)is the sixth most frequently occurring malignancies and the third leading cause of cancer death worldwide.Sepantronium bromide(YM155)is a small molecule inhibitor of survivin,which has broad-spectrum anticancer therapeutic effects in various xenograft models.However,several-day continuous infusion is required to achieve greater antitumor efficacy because of rapid elimination from the blood circulation.Herein,a SMMC-7721 cancerous cyto-membrane-cloaked drug delivery system(DDS)(named as iM7721@GQD-YM),was developed for co-encapsulation of YM155 and graphene quantum dots(GQDs).Cytomembrane coating endowed iM7721@GQD-YM with effective targeting for homologous HC cells,excellent biocompatibility and favorable immunocompatibility for in vivo application.Surface decoration of iRGD peptide further enhanced its tumor targeting activity by iRGD-integrin recognition.In addition,under the irradiation of near-infrared ray(NIR),GQDs can directly kill tumors through photothermal effect and cause cell membrane rupture,accurately releasing YM155 at tumor sites.The physicochemical properties,in vivo and ex vivo anti-tumor efficacy,and mechanisms of iM7721@GQD-YM nanoparticles(NPs)were systematically investigated in this work.The experimental results clearly indicate that the versatile biomimetic DDS holds great potential for the treatment of HC,which merits further investigation in both pre-clinical and clinical studies.
基金sponsored in part by National Key Research and Development Plan (2016YFE0119200)partially supported by the National Natural Science Foundation of China (NSFC) on Grants 81402856 and 81361140344 (A3 project)+1 种基金Tianjin Municipal Science and Technology Commission (Grant 15JCYBJC28700)the National Key Basic Research Program of China (Grant 2013CB932502)
文摘RNAi technology has aroused wide public interest due to its high efficiency and specificity to treat multiple types of diseases. However, the effective delivery of siRNA remains a challenge due to its large molecular weight and strong anionic charge. Considering their remarkable functions in vivo and features that are often desired in drug delivery carriers, biomimetic systems for siRNA delivery become an effective and promising strategy. Based on this, covalent attachment of synthetic cell penetrating peptides(CPP) to siRNA has become of great interest. We developed a monomeric covalent conjugate of low molecular weight protamine(LMWP, a well-established CPP) and siRNA via a cytosol-cleavable disulfide linkage using PEG as a crosslinker. Results showed that the conjugates didn't generate coagulation, and exhibited much better RNAi potency and intracellular delivery compared with the conventional charge-complexed CPP/siRNA aggregates. Three different synthetic and purification methods were compared in order to optimize synthesis efficiency and product yield. The methodology using hetero-bifunctional NHS–PEG–OPSS as a crosslinker to synthesize LMWP–siRNA simplified the synthesis and purification process and produced the highest yield. These results pave the way towards siRNA biomimetic delivery and future clinical translation.